SMARCA4 and acute myeloid leukemia: A recent study found that the viability of a variety of AML cell lines was substantially decreased by the simultaneous loss of BRM and BRG1 function, which was achieved either by knock-down approaches or the use of allosteric dual inhibitors like BRM011 and BRM014 [131].